Strides Arcolab announced two of its subsidiaries —Strides Pharma Global Pte Ltd (Singapore), and Strides (Australia) Pharma Pty Ltd — had signed definitive agreements with certain wholly-owned subsidiaries of Aspen Pharmacare Holdings Ltd to acquire their generic pharmaceutical business in Australia, along with certain branded pharmaceutical assets.
The acquisition is valued at A$380 million (Rs 1,900 crore).
The acquisition is valued at A$380 million (Rs 1,900 crore).
No comments:
Post a Comment